Clinical trial / 2017
Single-dose Mucuna pruriens seed powder showed noninferior motor improvements with fewer dyskinesias and adverse events than standard levodopa/benserazide.
Eighteen patients with advanced Parkinson disease received single doses of Mucuna pruriens (MP) powder (high-dose 17.5 mg/kg, low-dose 12.5 mg/kg, or 3.5 mg/kg with benserazide), dispersible levodopa with benserazide (LD+DDCI, 3.5 mg/kg), levodopa alone (17.5 mg/kg), or placebo in randomized order. Compared to LD+DDCI, low-dose MP produced similar motor response with fewer dyskinesias and adverse events. High-dose MP induced greater motor improvement at 90 and 180 minutes, longer ON duration, fewer dyskinesias, and fewer adverse events than LD+DDCI and levodopa alone, with no differences in cardiovascular response.
- Study type
- Double-blind, randomized, controlled, crossover trial
- Who was studied
- 18 patients with advanced Parkinson disease
- What was measured
- Motor response at 90 and 180 minutes, ON duration, adverse events, blood pressure, heart rate, dyskinesia severity
THE PAPER
Mucuna pruriens in Parkinson disease: A double-blind, randomized, controlled, crossover study.
Cilia R, Laguna J, Cassani E, Cereda E, Pozzi NG, Isaias IU, Contin M, Barichella M, Pezzoli G. Neurology, 2017.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.